| 王晓韧 陈立艳 毕蔓茹 颜炳柱 康岚 杨鹏飞 李文松 杨宝山△.胸腺肽α1联合恩替卡韦对乙肝肝硬化患者乙型肝炎e 抗原的影响*[J].,2016,16(27):5306-5308 |
| 胸腺肽α1联合恩替卡韦对乙肝肝硬化患者乙型肝炎e 抗原的影响* |
| The Effect of Combination of Thymosin-α1 and Entecavir on the HBeAg ofPatients with HBV-liver Cirrhosis |
| |
| DOI： |
| 中文关键词: 胸腺肽α 恩替卡韦 乙肝肝硬化 HBeAg |
| 英文关键词: Thymosinα1 Entecavir Chronic viral hepatitis B HBeAg |
| 基金项目:黑龙江省教育厅科学技术研究（重点）项目(11551z010) |
|
| 摘要点击次数: 588 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：分析胸腺肽α1 联合恩替卡韦治疗对于乙肝肝硬化患者的乙型肝炎e抗原(HBeAg)的影响。方法：选取2013年4 月至
2016 年4 月于哈尔滨医科大学附属第二医院感染二科住院和门诊复查的患者50 例，随机将患者分为两组，应用胸腺肽alpha1 联合
恩替卡韦治疗的患者为实验组，共25 例，单一应用恩替卡韦治疗的患者为对照组，共25 例。比较两组患者治疗前和治疗半年后
的肝功能、乙肝病毒载量以及HBeAg定量。结果：治疗半年后，实验组患者的肝功能和乙肝病毒载量与对照组比较无明显差异
(P>0.05)，实验组的HBeAg量明显低于对照组(P<0.05)。结论：胸腺肽α1 联合恩替卡韦可以有效的降低HBeAg量，促进e 抗原转阴，减少病毒复制。 |
| 英文摘要: |
| Objective:To analyze the effect of combination of thymosinα1 with entecavir on the HBeAg of patients with HBV-liver
cirrhosis.Methods:50 cases of patients in the hospitalized and outpatient sections of Second Affiliated Hospital of Harbin Medical University
Communicable Diseases Department Two from April, 2013 to April, 2016 were selected and randomly divided into two groups.
25 cases of patients received the combination of Thymosinα1 with Entecavir were considered as the experimental group and 25 cases of
patients received single-agent Entecavir were considered as the control group. The liver function, levels of HBV DNA in serum and
HBeAg quantity after half a year's treatment were compared between two groups.Results:There was no significant difference in the liver
function, levels of HBV DNA in serum between two groups (P>0.05) after half a year's treatment, while the HBeAg quantity of experimental
group was obviously lower than that of the control group (P<0.05).Conclusion:The combination of thymosinα1 with entecavir
could effectively decrease the HBeAg quantity and promote HBeAg to become negative reducing virus copy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
